Source: Lieyun Network
Recently, Leman Biotech announced the completion of an over 100 million RMB Series A financing round, led by Fuhui Venture Capital, with participation from Junyi Investment and XtalPi, among others.
The funds from this round of financing will be mainly used for the IND application of core CAR-T cell drugs, the research and development of automated production processes, and the acceleration of the clinical transformation of metabolism-enhanced solid tumor cell therapy drugs.
Leman Biotech is an innovative drug developer specializing in cancer immunotherapy and is an immunometabolism-focused company at the clinical stage. The company combines its innovative technology of immune-metabolic reprogramming (Meta 10) with AI, focusing on the research, development, manufacturing, and commercialization of novel cancer immunotherapy drugs. It aims to improve response rates and efficacy in cancer immunotherapy to achieve a cure for solid tumors. Based on two research achievements from EPFL, the company’s team has developed the world's first Meta 10 immune-metabolic reprogramming technology, establishing proprietary platforms including an immune-metabolic reprogramming biologic macromolecule drug platform, a metabolically enhanced immune cell therapy platform, and an AI-driven super immunomodulatory factor R&D platform.
According to the introduction on Leman Biotech Co., Ltd's official website, the company's core technology Meta 10 has demonstrated significant potential in curing solid tumors. Relevant results were published in the top international academic journal Nature Immunology, and two PCT patents (covering major economies worldwide) as well as two Chinese patents have been filed. Currently, 70% of the company’s senior R&D staff come from prestigious universities both within and outside China and possess extensive industrialization experience, with multiple R&D pipelines progressing smoothly.